CTIS2022-501744-15-00进行中（未招募）1 期
I8F-MC-GPIJ: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 15,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Be overweight or have obesity, Are over age 40 and have cardiovascular disease at least 3 months before study start, Women at least 55 years of age without established heart disease but have cardiovascular risk factors, such as smoke tobacco, abnormal levels of fats (lipids) in the blood, high blood pressure, or kidney disease., Men at least 50 years of age without established heart disease but have cardiovascular risk factors, such as smoke tobacco, abnormal levels of fats (lipids) in the blood, high blood pressure, or kidney disease.
排除标准
- •Have type 1 diabetes or type 2 diabetes at the beginning of the study, Have any of the cardiovascular conditions such as: heart attack, stroke, procedure to treat coronary artery disease, or heart failure requiring IV medication or left ventricular assist device within 3 months before the start of the study
研究者
相似试验
进行中（未招募）
1 期
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerProstate CancerCTIS2023-506777-36-00Eli Lilly & Co.304
招募中
1 期
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)Cardiovascular Disease, ObesityCTIS2023-503659-88-00Eli Lilly & Co.1,800
招募中
1 期
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)Alopecia areata (AA)CTIS2022-502700-78-00Eli Lilly & Co.603
招募中
1 期
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES)CTIS2023-508630-34-00Eli Lilly & Co.10,000
招募中
1 期
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)Type 2 DiabetesCTIS2023-507280-18-00Eli Lilly & Co.520